LianBio - ADR

LIAN | $4.92 0.41% 0.41% 410K

(0.0% 1d) (0.0% 1m) (122.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40.69% volume)
Earnings Calendar:
Market Cap: $ 531,668,179

Sec Filling | Patents | 2021 employees

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

add to watch list Paper trade email alert is off

Nukkleus Inc.

NUKK | $0.8098 -6.24% 110K

Professional, Scientific, and T...

(0.0% 1d) (-6.6% 1m) (1950.1% 1y) (0.0% 2d) (0.0% 3d) (-12.0% 7d) (-21.59% volume)
Earnings Calendar:
Market Cap: $ 0
https://www.nukk.com/
Sec Filling | Patents | 1 employees

(US) nukkleus, inc. (otc: nukk) is a fintech group that acquires, builds and scales blockchain and digital financial services businesses. the portfolio serves b2b and institutional clients with the aim of disrupting the banking & investment industry for the better.

add to watch list Paper trade email alert is off

Pyxis Oncology Inc

PYXS | $4.7 -0.84% -0.85% 260K

Professional, Scientific, and T...

(0.0% 1d) (-3.3% 1m) (48.1% 1y) (0.0% 2d) (0.0% 3d) (-6.7% 7d) (26.55% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 273,226,863
https://pyxisoncology.com
Sec Filling | Patents | 2021 employees

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

cancer t-cell

add to watch list Paper trade email alert is off

Acumen Pharmaceuticals Inc

ABOS | $3.51 -0.57% -0.57% 220K

Professional, Scientific, and T...

(0.0% 1d) (-11.3% 1m) (-3.3% 1y) (0.0% 2d) (0.0% 3d) (-4.9% 7d) (NaN% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 210,880,021
https://www.acumenpharm.com
Sec Filling | Patents | 2021 employees

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Design Therapeutics Inc

DSGN | $3.7 -2.38% -2.43% 210K

Professional, Scientific, and T...

(0.0% 1d) (50.4% 1m) (-27.0% 1y) (0.0% 2d) (0.0% 3d) (-0.3% 7d) (310.36% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 209,028,803
https://www.designtx.com
Sec Filling | Patents | n/a employees

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.

treatment

add to watch list Paper trade email alert is off

ECO INNOVATION GROUP, INC.

ECOX | $0.0001 0.0% 64M

Professional, Scientific, and T...

(0.0% 1d) (-50.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (12284.25% volume)
Earnings Calendar:
Market Cap: $ 243,235

Sec Filling | Patents | n/a employees

eco innovation group, inc. provides water treatment unit to convert contaminated water into safe drinking water. the company is based in palm beach, florida.

add to watch list Paper trade email alert is off

VERDE BIO HOLDINGS, INC.

VBHI | $0.0003 60.0% 10M

Professional, Scientific, and T...

(0.0% 1d) (-25.0% 1m) (-57.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.96% volume)
Earnings Calendar:
Market Cap: $ 606,246
https://www.verdebh.com/
Sec Filling | Patents | 1 employees

(US)

add to watch list Paper trade email alert is off